ASSOCIATION OF SERUM SIALIC ACID AND SERUM URIC ACID LEVELS WITH FASTING BLOOD GLUCOSE LEVELS IN TYPE-2 DIABETES MELLITUS PATIENTS

  • YENDREMBAM PASCAL SINGH Department of Biochemistry, School of Medical Sciences and Research and Sharda Hospital, Sharda University, Greater Noida, Uttar Pradesh, India.
  • VED PAL SINGH PUNIA Department of Medicine, School of Medical Sciences and Research and Sharda Hospital, Sharda University, Greater Noida, Uttar Pradesh, India.
  • GLADYS RAI Department of Biochemistry, School of Medical Sciences and Research and Sharda Hospital, Sharda University, Greater Noida, Uttar Pradesh, India.
  • MANOJ KUMAR NANDKEOLIAR Department of Biochemistry, School of Medical Sciences and Research and Sharda Hospital, Sharda University, Greater Noida, Uttar Pradesh, India.

Abstract

Objectives: The objective of the study was to estimate the serum sialic acid and serum uric acid levels in patients with type-2 diabetes mellitus and non-diabetic individuals and determining the association of serum sialic acid and serum uric acid levels with fasting blood glucose levels in patients with type-2 diabetes mellitus and also in non-diabetic individuals.


Methods: The study was a cross-sectional analysis where 70 individuals in the age group of 30–70 years participated during 6 months period. This included two groups, one for type-2 diabetes patients as cases and other non-diabetics as controls. In each group, 35 individuals participated. There were 15 males and 20 females in type-2 diabetic group and 16 males and 19 females in non-diabetic group. Fasting blood glucose, serum sialic acid, and serum uric acid were estimated in both the groups.


Results: In this study, the serum sialic acid levels of type-2 diabetes mellitus were shown to be increased (76.60 ± 7.89) when compared to non-diabetics (39.66 ± 9.55) with a statistically significant, p < 0.001. The serum uric acid concentrations were also found to be slightly elevated in type-2 diabetes mellitus (4.48 ± 0.79) when compared to non-diabetics (4.28 ± 0.89) with a statistically non-significant, p = 0.323.


Conclusion: Based on this study, it is concluded that serum sialic acid and serum uric acid levels have been found to be positively associated with type- 2 diabetes mellitus in both men and women, indicating the risk of developing microvascular complications in those patients. Therefore, estimating the sialic acid and uric acid levels can aid in the early diagnosis and prevention of microvascular complications caused by type-2 diabetes mellitus.

Keywords: Sialic acid, Uric acid, Type-2 Diabetes Mellitus, Microvascular complication

References

1. Jain R, Jain P, Jain P. A review on treatment and prevention of diabetes mellitus. Int J Curr Pharm Res 2016;8:16-8.
2. Andayani TM, Izham M, Ibrahim M, Asdie AH. The association of diabetes-related factor and quality of life in Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2010;2:139-45.
3. Rabba AK, Aljiris WS, Ahmed NJ, Alkharfy KM. Medication adherence in Type 2 diabetic patients: A study in Saudi Arabia. Int J Pharm Pharm Sci 2017;9:247-50.
4. Prajna K, Kumar JA, Rai S, Shetty SK, Rai T. Predictive value of serum sialic acid in Type-2 diabetes mellitus and its complication (nephropathy). J Clin Diagn Res 2013;7:2435-7.
5. Jafri SA, Rehman KU, IIyas N, Imran AB, Qasim M, Zahra M. Evaluation of serum sialic acid and other risk factors in diabetes mellitus. Acad J 2017;16:2326-30.
6. Nayak SB, Bhaktha G. Relationship between sialic acid and metabolic variables in Indian Type 2 diabetic patients. Lipids Health Dis 2005;4:1-4.
7. Pickup JC, Mattock MB, Chusney GD, Burt D. NIIDM as disease of the innate immune system: Association of the acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92.
8. Nayak SB, Duncan H, Lallo S, Maraj K, Matmungal V, Matthews F, et al. Correlation of microalbumin and sialic acid with anthropometric variables in Type-2 diabetic patients with and without nephropathy. Vascular Health Risk Management 2008;4:243-7.
9. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of Type 2 diabetes. Diabetes Care 2004;27:813-23.
10. Crook M, Tutt P, Pickup JC. Elevated serum sialic acid concentration in noninsulin dependent diabetes and its relationship to blood pressure and retinopathy. Diabetes Care 1993;16:57-60.
11. Crook MA, Earle K, Morocutti A, Yip A, Viberti GC, Pickup JC. Serum sialic acid, a risk factor for cardiovascular disease, is increased in IDDM patients with microalbuminuria and clinical proteinuria. Diabetes Care 1994;17:305-10.
12. Bhole V, Choi JW, Kim SW, Vera de M, Choi H. Serum uric acid levels and the risk of Type 2 diabetes: A prospective study. Am J Med 2010;123:957-61.
13. Talwar T, Tanwar L, Gupta M, Singal KK. Study of serum uric acid levels in Type 2 diabetes mellitus patients. IOSR J Dent Med Sci 2017;16:83-9.
14. Dehghan A, Van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for Type 2 diabetes. Diabetes Care 2008;31:361-2.
15. Chien KL, Chen MF, Hsu HC, Chang WT, Su TC, Lee YT, et al. Plasma uric acid and the risk of Type 2 diabetes in a Chinese community. Clin Chem 2008;54:310-6.
16. Kramer CK, Von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident Type 2 diabetes in individuals with impaired fasting glucose. The rancho Bernardo study. Diabetes Care 2009;32:1272-3.
17. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003;18:523-30.
18. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of Type 2 diabetes. Diabetes Care 2009;32:1737-42.
19. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid a facet of hyperinsulinaemia. Diabetologia 1987;30:713-8.
20. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka health survey. J Hypertens 2001;19:1209-15.
21. Oda E, Kawai R, Sukumaran V, Watanabe K. Uric acid is positively associated with metabolic syndrome but negatively associated with diabetes in Japanese men. Intern Med 2009;48:1785-91.
22. Nan H, Dong Y, Gao W, Tuomilehto J, Qiao Q. Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract 2007;76:68-74.
23. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes. Diabetes Care 2019;42:S13-28.
24. Sydow G, Wittmann W, Bender E, Starick E. The sialic acid content of the serum of cattle infected with bovine leukosis virus. Arch Exp Veterinarmed 1988;42:194-7.
25. Ismail SA, Bakeer H, Aziz MM, Fahmy IA, El Hefni M, Nabil S, et al. Role of elevated serum sialic acid in the progression of both diabetic retinopathy and diabetic nephropathy. J Med Sci Clin Res 2015;3:8422-31.
26. Prakash S, Sudha S. Relationship between nitric oxide and sialic acid concentrations in South Indian Type 2 diabetic patients. Adv Appl Sci Res 2013;4:258-62.
27. Ghosh J, Datta S, Pal M. Role of sialic acid in prediction of diabetic nephropathy. AI Ameen J Med Sci 2016;9:58-64.
28. Causevic A, Semiz S, Dzankovic AM, Cico B, Dujic T, Malenica M, et al. Relevance of uric acid in progression of Type 2 diabetes mellitus. Bosnian J Basic Med Sci 2010;10:54-9.
29. Hussain A, Latiwesh OB, Ali F, Younis MY, Alammari JA. Effects of body mass index, glycemic control, and hypoglycemic drugs on serum uric acid levels in Type 2 diabetic patients. Cureus 2018;10:e3158.
30. Rathore A, Samota MK, Bedwal H, Tank L, Jain SC. Serum uric acid and Type 2 diabetes mellitus complications. J Evid Based Med Healthc 2018;5:870-3.
Statistics
64 Views | 84 Downloads
Citatons
How to Cite
PASCAL SINGH, Y., V. P. SINGH PUNIA, G. RAI, and M. K. NANDKEOLIAR. “ASSOCIATION OF SERUM SIALIC ACID AND SERUM URIC ACID LEVELS WITH FASTING BLOOD GLUCOSE LEVELS IN TYPE-2 DIABETES MELLITUS PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 6, Apr. 2020, pp. 83-86, doi:10.22159/ajpcr.2020.v13i6.37349.
Section
Original Article(s)